Cirrhosis News and Research

Latest Cirrhosis News and Research

South West Liver Unit researchers receive grants for developing Hepatitis C vaccine

Researchers at the South West Liver Unit, based at Plymouth Hospitals NHS Trust and supported by the Peninsula Medical School, are working to save more lives and improve the health of Hepatitis C sufferers around the world by developing a vaccine for the disease.

5 Mar 2010

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.

3 Mar 2010

Abbott and Enanta advance treatment for Hepatitis C

Abbott and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials.

2 Mar 2010

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity. Results of this study appear in the March issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Mar 2010

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models.

1 Mar 2010

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Widely used biomarkers are not optimal in early detection of liver cancer, the third most common cause of cancer-related death worldwide, according to a new study published in this month's Gastroenterology.

26 Feb 2010

Combining DCP and AFP biomarkers may improve early detection of liver cancer

While biomarkers are needed to complement ultrasound in the early detection of hepatocellular carcinoma (HCC; liver cancer), neither des-gamma-carboxy prothrombin (DCP) nor the most widely used biomarker, alpha fetoprotein (AFP), is optimal, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

26 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

$NovaShunt initiates study to evaluate AFS for refractory ascites patients$

NovaShunt initiates study to evaluate AFS for refractory ascites patients

NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.

11 Feb 2010

Study explores link between HBV genotype C and liver cirrhosis

Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported.

10 Feb 2010

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune liver diseases. However, further studies are necessary in order to validate the diagnostic utility of IgM and IgG immunohistochemistry in this specific scenario.

10 Feb 2010

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.

9 Feb 2010

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

With most liver cancer caused by undetected or untreated hepatitis B or C viral infection, the 22,000 new cases of liver cancer that are diagnosed each year could be dramatically reduced if Congress took decisive action to close the funding gap for federal viral hepatitis education, screening, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) said today.

4 Feb 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

28 Jan 2010

Patients with NAFLD have higher overall mortality rate, say researchers

Researchers from the Karolinska Institute determined that patients with nonalcoholic fatty liver disease (NAFLD) have a higher overall mortality rate compared with the general population.

28 Jan 2010

Budgetary freeze will impact over 5M Americans afflicted with chronic viral hepatitis

Ms. Lorren Sandt, Chair of the National Viral Hepatitis Roundtable (NVHR) issued the following statement in advance of the President's State of the Union Address. NVHR is a coalition of more than 150 public, private, and voluntary organizations dedicated to reducing the incidence of infection, morbidity, and mortality from chronic viral hepatitis that afflicts more than 5 million Americans:

28 Jan 2010

TE can be accurately performed in majority of NAFLD patients to exclude advanced fibrosis

Researchers from France and Hong Kong determined that transient elastography (TE), a noninvasive, ultrasonic imaging modality, can be accurately performed in the majority of patients with nonalcoholic fatty liver disease (NAFLD) to exclude advanced fibrosis. Full findings of this study, funded by the Chinese University of Hong Kong, appear in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

27 Jan 2010

Cirrhosis News and Research

Latest Cirrhosis News and Research

South West Liver Unit researchers receive grants for developing Hepatitis C vaccine

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Abbott and Enanta advance treatment for Hepatitis C

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Combining DCP and AFP biomarkers may improve early detection of liver cancer

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

NovaShunt initiates study to evaluate AFS for refractory ascites patients

Study explores link between HBV genotype C and liver cirrhosis

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

Closing funding gap for federal viral hepatitis education, screening and surveillance programs stops liver cancer

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Patients with NAFLD have higher overall mortality rate, say researchers

Budgetary freeze will impact over 5M Americans afflicted with chronic viral hepatitis

TE can be accurately performed in majority of NAFLD patients to exclude advanced fibrosis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Cirrhosis News and Research

Latest Cirrhosis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in